Repros Therapeutics Inc. shares were halted in premarket trade Monday on news that the Food and Drug Administration would continue a partial clinical hold for its drug for uterine fibroids, or tumors in the uterus. The FDA told Repros that it will consult with its liver experts about the liver toxicity that's been previously experienced with the drug, Proellex. Repros will submit additional information to the FDA for its internal advisory liver team to consider within a month, it said. The FDA has previously put development programs for Proellex on clinical holds because of safety concerns, including a 2010 study of the drug's safety and efficacy and a 2012 study of the drug in endometriosis, a condition that causes severe pelvic abdominal pain. Repros shares were valued at $1.11 as of Friday's close. Shares have dropped 20.7% over the last three months, compared with a 3.8% rise in the S&P 500.